Marinus Pharmaceuticals (NASDAQ:MRNS) released its quarterly earnings data on Tuesday, March 6th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.07), Yahoo Finance reports.
Marinus Pharmaceuticals (MRNS) traded down $0.11 during mid-day trading on Wednesday, hitting $4.28. The stock had a trading volume of 703,569 shares, compared to its average volume of 1,200,000. The company has a market cap of $173.04, a price-to-earnings ratio of -5.22 and a beta of 2.42. Marinus Pharmaceuticals has a 52 week low of $1.13 and a 52 week high of $9.87.
In other news, major shareholder Bain Capital Life Sciences Inv sold 1,272,547 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $7.88, for a total value of $10,027,670.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Christopher Michael Cashman sold 9,566 shares of the business’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $6.28, for a total value of $60,074.48. Following the completion of the transaction, the chief executive officer now directly owns 247,903 shares in the company, valued at $1,556,830.84. The disclosure for this sale can be found here. Insiders sold a total of 2,107,660 shares of company stock worth $16,774,106 over the last three months. 4.60% of the stock is owned by company insiders.
Several research firms have recently weighed in on MRNS. ValuEngine lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Laidlaw began coverage on Marinus Pharmaceuticals in a research note on Thursday, December 14th. They issued a “buy” rating and a $18.00 price objective on the stock. BidaskClub lowered Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, HC Wainwright began coverage on Marinus Pharmaceuticals in a research note on Thursday, February 15th. They issued a “buy” rating and a $33.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $20.67.
TRADEMARK VIOLATION NOTICE: “Marinus Pharmaceuticals (MRNS) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/03/14/marinus-pharmaceuticals-mrns-releases-quarterly-earnings-results-misses-expectations-by-0-07-eps.html.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.